Lila-Sabrina Fetita

Clinical Research Director
Sanofi, Paris, France
Paris, Ile-de-France, France

Presentation(s):

• OC 50.1 - First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study

  Tuesday, June 25, 2024
  09:30 – 09:45 ICT